Meeting
2021 Genitourinary Cancers Symposium
Enzalutamide plus androgen deprivation therapy (ADT) versus flutamide plus ADT in men with castration-resistant prostate cancer (CRPC): AFTERCAB.
Authors
Hiroji Uemura
Yokohama City University Medical Center, Yokohama, Japan
Hiroji Uemura , Kazuki Kobayashi , Akira Yokomizo , Shiro Hinotsu , Shigeo Horie , Yoshiyuki Kakehi , Seiji Naito , Norio Nonomura , Osamu Ogawa , Mototsugu Oya , Kazuhiro Suzuki , Atsushi Saito , Satoshi Uno , Hideyuki Akaza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02918968
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 81)
DOI
10.1200/JCO.2021.39.6_suppl.81
Abstract #
81
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: A retrospective study.
First Author: Kosuke Hamada
Poster
2021 Genitourinary Cancers Symposium
PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.
First Author: Ugo De Giorgi
Poster
2023 ASCO Genitourinary Cancers Symposium
A study to determine enzalutamide long term safety and efficacy for men with castration-resistant prostate cancer: A multicenter, prospective DELC study.
First Author: Koji Hatano
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.
First Author: Shunsuke Kamijo